Home/Filings/4/0001235802-23-000110
4//SEC Filing

STANKOVICH THOMAS 4

Accession 0001235802-23-000110

CIK 0001427570other

Filed

Nov 7, 7:00 PM ET

Accepted

Nov 8, 4:16 PM ET

Size

11.1 KB

Accession

0001235802-23-000110

Insider Transaction Report

Form 4
Period: 2023-08-04
STANKOVICH THOMAS
Chief Financial Officer
Transactions
  • Sale

    Common Stock, $0.001 par value per share

    2023-08-04$1.43/sh108$15423,276 total
  • Sale

    Common Stock, $0.001 par value per share

    2023-09-01$0.89/sh118$10523,119 total
  • Sale

    Common Stock, $0.001 par value per share

    2023-10-25$0.27/sh131$3522,949 total
  • Sale

    Common Stock, $0.001 par value per share

    2023-08-24$1.42/sh39$5523,237 total
  • Sale

    Common Stock, $0.001 par value per share

    2023-10-11$0.93/sh39$3623,080 total
Footnotes (1)
  • [F1]On July 22, 2021, Mr. Stankovich was awarded an aggregate of 7,455 restricted stock units, all of which, including the unvested portion, were reported on a Form 4 filed on September 17, 2021. The shares reported under this Form 4 as being disposed of were sold to cover taxes in connection with the vesting of a portion of those previously reported restricted stock units.

Issuer

ReShape Lifesciences Inc.

CIK 0001427570

Entity typeother

Related Parties

1
  • filerCIK 0001181166

Filing Metadata

Form type
4
Filed
Nov 7, 7:00 PM ET
Accepted
Nov 8, 4:16 PM ET
Size
11.1 KB